English, Article edition: Cost-Effectiveness Analysis of Pneumococcal Vaccination for Elderly Individuals in The Netherlands Maarten J. Postma; Marielouise A. Heijnen; Johannes C. Jager

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/119543
Physical Description
  • article
Language
  • English

Edition details

Title
  • Cost-Effectiveness Analysis of Pneumococcal Vaccination for Elderly Individuals in The Netherlands
Author
  • Maarten J. Postma
  • Marielouise A. Heijnen
  • Johannes C. Jager
Physical Description
  • article
Notes
  • Objective: To assess the cost effectiveness (net costs per life year gained) of pneumococcal vaccination of elderly individuals aged 65 years and over in The Netherlands. Design and setting: A pharmacoeconomic analysis was conducted from the healthcare perspective in The Netherlands. The gender- and age-specific modelling framework linked epidemiological aspects of invasive pneumococcal disease (e.g. incidence, mortality, life years lost) to vaccination and hospital resource use. To derive 90% confidence limits for net costs per life year gained a stochastic analysis was performed. Intervention: Pneumococcal vaccination in the elderly with the 23-valent vaccine. Effectiveness of the vaccine in preventing invasive pneumococcal disease was derived from international studies. Main outcome measures and results: Pneumococcal vaccination in the elderly was not found to be cost saving. At baseline, stochastic and univariate sensitivity analysis net costs per life year gained were estimated to be between 6000 and 16 000 euro (EUR) [EUR1 =​ 1.1 US dollars; cost level 1995]. A scenario analysis on alternative age-dependent vaccination strategies indicated even higher net costs per life year gained, up to EUR28 000 for vaccinating only those elderly aged 85 years and over. Conclusions: Pneumococcal vaccination is associated with net costs per life year gained of EUR10 100 (at baseline assumptions). These costs are higher than those for influenza vaccination (EUR5500). Our pharmacoeconomic approach, which needs to be considered in conjunction with social, psychological and budgetary issues, is intended to contribute to rational decision-making in healthcare policy.
  • Cost effectiveness, Elderly, Pharmacoeconomics, Pneumococcal infections, Pneumococcal vaccine, Vaccines
  • RePEc:wkh:phecon:v:19:y:2001:i:2:p:215-222
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment